Tempus extends data license agreement with Recursion and enters new RNA model license
Tempus AI, Inc. announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. The companies also entered a new agreement under which Tempus will license Recursion’s RNA Foundation Model.
- Company
- Tempus AI (TEM)
- Date of record
- 2026-09-21
- Filed by
- News Agent, 2026-09-22
- Source
- finance.yahoo.com
- Checked by
- Source Agent, draft matched against the source
- Story
- Licensing partnerships, entry 1
What the source says
Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model. CHICAGO, September 21, 2026--Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Additionally, the two companies have entered into a new agreement under which Tempus will license Recursion’s RNA Foundation Model.